Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis.

Drug development research - 1 Aug 2021

Ortega-Vázquez Alberto, Mayen-Lobo Yerye G, Dávila-Ortiz de Montellano David J, Tristán-López Luis, Aviña-Cervantes Carlos L, Ríos Camilo, López-López Marisol, Monroy-Jaramillo Nancy

Abstract excerpt

Clozapine (CLZ) is an atypical antipsychotic and the gold standard for refractory psychosis treatment. However, there is little information regarding pharmacogenetics of CLZ in patients with refractory psychosis and its clinical correlation with alcohol intake. Although neurological effects of CLZ in patients with concomitant alcohol intake are documented, its use is very common in patients with psychosis. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Drinking
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clozapine

Share to Cross-Sectional Studies

Share to Cytochrome P-450 CYP1A2

Share to Drug-Related Side Effects and Adverse Reactions

Share to Pharmacogenetics

Share to Psychotic Disorders

Source

Identifiers

PMID: 33336447
DOI: 10.1002/ddr.21774

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis.PMID 33336447Read ↗

Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.Semantic proximity Read ↗

Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia.Semantic proximity Read ↗

The Potential Role of POR*28 and CYP1A2*F Genetic Variations and Lifestyle Factors on Clozapine and N-DesmethylClozapine Plasma Levels in Schizophrenia Patients.Semantic proximity Read ↗

Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an updateSemantic proximity Read ↗

CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.Semantic proximity Read ↗

Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.Semantic proximity Read ↗

Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.Semantic proximity Read ↗

Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19Semantic proximity Read ↗

Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia.Semantic proximity Read ↗

Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine MetabolismSemantic proximity Read ↗

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.Semantic proximity Read ↗

Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.